Amgen (NASDAQ:AMGN) exceeds Q3 2026 expectations, full-year outlook slightly exceeds expectations

What happened

Amgen beat Wall Street's revenue expectations in Q3 2026, with revenue up 8.5% year on year to $10.37 billion. Its non-GAAP profit of $6.45 per share was 11.6% above analysts' consensus estimates. The company also raised its full-year revenue guidance to $39.3 billion at the midpoint.

Confirmed

Global impact / market context

A revenue and profit beat plus higher full-year guidance suggests Amgen is selling more and keeping more profit per sale, which can support the stock and fund future research and capital spending. Free cash flow margin, or cash left after running the business, fell to 35.3% from 44.4%.

Analyst inference

Investors compare results with analyst consensus estimates, which are average forecasts. Amgen's revenue beat by 3.1% and profit beat by 11.6%, while full-year revenue guidance came in 0.8% above consensus. This positions the company ahead of expectations within the biotech sector covered by the report.

Analyst inference

What to watch

1. Amgen raised full-year adjusted EPS guidance to $23.30 at the midpoint, a 1.7% increase, so watch whether later results track toward that figure. Confirmed
2. Watch whether free cash flow margin recovers from 35.3%, since weaker cash generation could limit buybacks, debt repayment, or capital spending plans. Proposed
3. Watch whether the 8.5% revenue growth continues, because slower sales would make the raised full-year guidance harder to meet and could pressure investor positioning in AMGN shares. Analyst inference

Evidence

• stockstory.org